Blog
RSS FeedPosted by Michael Wonder on 23 Apr 2019
Additional embargo period following revised CDEC recommendations
17 April 2019 - Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an ...
Posted by Michael Wonder on 03 Mar 2019
Biogen responds to CADTH’s updated recommendation regarding coverage for Spinraza
1 March 2019 - CADTH has expanded their recommendations for public reimbursement for SMA patients. ...
Posted by Michael Wonder on 29 Oct 2018
Mavenclad (cladribine tablets) receives positive CADTH Canadian Drug Expert Committee recommendation
29 October 2018 - Funding recommendation marks an important step to provide access to this innovative new oral treatment for Canadians ...
Posted by Michael Wonder on 08 Oct 2018
Committee recommends against funding $250,000-a-year Orkambi cystic fibrosis drug
4 October 2018 - Canadian governments should not pay for a $250,000-a-year cystic fibrosis medication because it is not clear ...
Posted by Michael Wonder on 10 Sep 2018
Canadian Dermatology Association and Canadian Society of Allergy and Clinical Immunology issue joint statement against the Canadian Agency for Drugs and Technologies in health recommendation
10 September 2018 - Many Canadian eczema sufferers are dealt a difficult blow; many patients face a future with no access ...
Posted by Michael Wonder on 01 Aug 2018
Canada’s drug agency advised against reimbursing a costly eczema drug — here’s why people are worried
30 July 2018 - Five years ago, Felix Tang’s eczema was a debilitating accompaniment to stress. The chronic inflammatory skin ...
Posted by Michael Wonder on 10 Jul 2018
Sanofi denounces CADTH negative recommendation on Dupixent
10 July 2018 - Sanofi Genzyme said that it is disappointed with the recent recommendation by CADTH to not reimburse Dupixent, ...
Posted by Michael Wonder on 09 Jul 2018
CADTH publishes final CDEC recommendation for dupilumab
9 July 2018 - CADTH has completed its assessment of Dupixent (dupilumab) for the treatment of patients with atopic dermatitis. ...
Posted by Michael Wonder on 13 Mar 2018
Price and clinical factors impact Canadian orphan drug recommendation rates
11 March 2018 - Canada’s Common Drug Review (CDR), which provides recommendations on public payer reimbursement for all non-oncology drugs, ...
Posted by Michael Wonder on 27 Feb 2018
Sobi’s Orfadin (nitisinone) receives positive reimbursement recommendation for the treatment of HT-1 from CADTH Canadian Drug Expert Committee
27 February 2018 - Sobi announced today that the CADTH Canadian Drug Expert Committee has issued a conditional positive reimbursement ...
Posted by Michael Wonder on 07 Feb 2018
AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Maviret – an oral therapy for the treatment of patients with hepatitis C
6 February 2018 - Maviret previously received a Notice of Compliance from Health Canada on 16 August 2017. ...
Posted by Michael Wonder on 03 Aug 2017
Sandoz Erelzi (etanercept) receives positive reimbursement recommendation from Common Drug Review for treatment of multiple inflammatory diseases
2 August 2017 - Positive recommendation moves Erelzi closer to federal, provincial and territorial drug plan reimbursement. ...
Posted by Michael Wonder on 29 May 2017
CADTH publishes final recommendations for two Servier medicines
25 May 2017 - CADTH has published outcomes for edoxaban tosylate (Lixiana) and ivabradine hydrochloride (Lancora). ...
Posted by Michael Wonder on 25 May 2017
CADTH recommends reimbursement of Gilead's Odefsey
25 May 2017 - The CADTH Canadian Drug Expert Committee has recommended that emtricitabine/rilpivirine/tenofovir alafenamide be reimbursed as a complete ...
Posted by Michael Wonder on 10 May 2017
Provincial drug plans, including Ontario and BC, make Entyvio (vedolizumab) available to treat inflammatory bowel disease
9 May 2017 - Gut-selective treatment now funded publicly for Canadians with ulcerative colitis and Crohn's disease. ...